兩連板的冠昊生物(300238.SZ):生物人工肝項目已獲幹細胞臨牀研究項目倫理審查批件
格隆匯3月10日丨連續2個漲停的冠昊生物(300238.SZ)發佈公告稱,公司於2020年3月11日在披露了《關於全資子公司合作研發項目的進展公告》,涉及生物人工肝項目已獲幹細胞臨牀研究項目倫理審查批件。除上述事項外:
公司前期披露的信息不存在需要更正、補充之處;公司目前經營正常,近期公司經營情況及內外部經營環境未發生重大變化;
公司未發現近期公共傳媒報道了可能對公司股票交易價格產生重大影響的未公開重大信息;
公司控股股東及實際控制人不存在關於公司應披露而未披露的重大事項,或處於籌劃階段的重大事項等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.